The ceramide- and phosphatidylcholine- based coronary event risk test2 (CERT2) and cardiovascular mortality in men and women with type 2 diabetes

A Leiherer,A Mader,M Laaperi,L Sprenger,V Grabher,P Fraunberger,A Muendlein,R Laaksonen,C.H Saely,A Jylha,B Larcher,M Maechler,H Drexel

doi:10.1016/j.atherosclerosis.2022.06.708

The ceramide- and phosphatidylcholine- based coronary event risk test2 (CERT2) and cardiovascular mortality in men and women with type 2 diabetes

A Leiherer, A Mader + Show 11 more

Open Access

https://doi.org/10.1016/j.atherosclerosis.2022.06.708

Copy DOI

Journal: Atherosclerosis

Publication Date: Aug 1, 2022

Affiliation: Vorarlberg Institute for Vascular Investigation and Treatment, Landeskrankenhaus Feldkirch, Zora Biosciences (Finland), Private University in the Principality of Liechtenstein, IVF Centers Prof. Zech

#Cardiovascular Mortality In Men #Cardiovascular Mortality In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and Aims : The recently introduced Coronary Event Risk Test version 2 (CERT2) is a validated cardiovascular risk predictor score that uses circulating ceramide and phosphatidylcholine concentrations. We here aimed at investigating the power of CERT2 to predict cardiovascular mortality in patients with type 2 diabetes (T2DM).

Full Text